收稿日期: 2023-08-22
网络出版日期: 2023-12-11
基金资助
北京市科技计划项目(Z191100006619110);中华国际医学交流基金会基金(Z-2018-40-2101)
卢情怡 , 艾尼扎提·哈斯木 , 李宇菲 , 李春 . 抗神经酰胺抗体在抗磷脂综合征中的分布及临床意义[J]. 北京大学学报（医学版）, 2023 , 55(6) : 1139 -1143 . DOI: 10.19723/j.issn.1671-167X.2023.06.029
| 1 | Garcia D , Erkan D . Diagnosis and management of the antiphospholipid syndrome[J]. N Engl J Med, 2018, 378 (21): 2010- 2021. |
| 2 | Miyakis S , Lockshin MD , Atsumi T , et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)[J]. J Thromb Haemost, 2006, 4 (2): 295- 306. |
| 3 | Hughes GR , Khamashta MA . Seronegative antiphospholipid syndrome[J]. Ann Rheum Dis, 2003, 62 (12): 1127. |
| 4 | Zietzer A , Düsing P , Reese L , et al. Ceramide metabolism in cardiovascular disease: A network with high therapeutic potential[J]. Arterioscler Thromb Vasc Biol, 2022, 42 (10): 1220- 1228. |
| 5 | Yuan H , Zhu B , Li C , et al. Ceramide in cerebrovascular diseases[J]. Front Cell Neurosci, 2023, 17, 1191609. |
| 6 | Shu H , Peng Y , Hang W , et al. Emerging roles of ceramide in cardiovascular diseases[J]. Aging Dis, 2022, 13 (1): 232- 245. |
| 7 | Alexandropoulou I , Grammatikopoulou MG , Gkouskou KK , et al. Ceramides in autoimmune rheumatic diseases: Existing evidence and therapeutic considerations for diet as an anticeramide treatment[J]. Nutrients, 2023, 15 (1): 229. |
| 8 | Radin M , Sciascia S , Erkan D , et al. The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort[J]. Semin Arthritis Rheum, 2019, 49 (3): 464- 468. |
| 9 | Yin W , Li F , Tan X , et al. Plasma ceramides and cardiovascular events in hypertensive patients at high cardiovascular risk[J]. Am J Hypertens, 2021, 34 (11): 1209- 1216. |
| 10 | 张鹏, 陈夏欢, 王昊, 等. 神经酰胺在心血管疾病预测价值中的研究进展[J]. 中国心血管杂志, 2020, 25 (2): 189- 192. |
| 11 | Bismuth J , Lin P , Yao Q , et al. Ceramide: A common pathway for atherosclerosis?[J]. Atherosclerosis, 2008, 196 (2): 497- 504. |
| 12 | Hamada Y , Nagasaki H , Fujiya A , et al. Involvement of de novo ceramide synthesis in pro-inflammatory adipokine secretion and adipocyte-macrophage interaction[J]. J Nutr Biochem, 2014, 25 (12): 1309- 1316. |
| 13 | Laaksonen R , Ekroos K , Sysi-Aho M , et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol[J]. Eur Heart J, 2016, 37 (25): 1967- 1976. |
| 14 | Vasile VC , Meeusen JW , Medina Inojosa JR , et al. Ceramide scores predict cardiovascular risk in the community[J]. Arterioscler Thromb Vasc Biol, 2021, 41 (4): 1558- 1569. |
| 15 | Chen WF , Lee JJ , Chang CC , et al. Platelet protease-activated receptor (PAR)4, but not PAR1, associated with neutral sphingomyelinase responsible for thrombin-stimulated ceramide-NF-κB signaling in human platelets[J]. Haematologica, 2013, 98 (5): 793- 801. |
| 16 | Pignatelli P , Ettorre E , Menichelli D , et al. Seronegative antiphospholipid syndrome: Refining the value of "non-criteria" antibodies for diagnosis and clinical management[J]. Haematologica, 2020, 105 (3): 562- 572. |
| 17 | Zhang S , Wu Z , Zhang W , et al. Clinical performance of non-criteria antibodies to phospholipids in Chinese patients with antiphospholipid syndrome[J]. Clin Chim Acta, 2019, 495, 205- 209. |
| 18 | Lopez LR , Dier KJ , Lopez D , et al. Anti-beta 2-glycoprotein Ⅰ and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome[J]. Am J Clin Pathol, 2004, 121 (1): 142- 149. |
| 19 | Castanon A , Pierre G , Willis R , et al. Performance evaluation and clinical associations of immunoassays that detect antibodies to negatively charged phospholipids other than cardiolipin[J]. Am J Clin Pathol, 2018, 149 (5): 401- 411. |
| 20 | Li S , Bai Y , Meng J , et al. Prevalence and diagnostic value of non-criteria antiphospholipid antibodies for antiphospholipid syndrome in Chinese patients[J]. Front Immunol, 2023, 14, 1107510. |
| 21 | Summers SA , Chaurasia B , Holland WL . Metabolic messengers: Ceramides[J]. Nat Metab, 2019, 1 (11): 1051- 1058. |
/
| 〈 |
|
〉 |
